

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

RN 9016-45-9 REGISTRY

CN Poly(oxy-1,2-ethanediyl), .alpha.-(nonylphenyl)-.omega.-hydroxy- (9CI)  
(CA INDEX NAME)

OTHER NAMES:

CN (Nonylphenoxy)polyethylene oxide

CN .alpha.-(Nonylphenyl)-.omega.-hydroxypoly(oxy-1,2-ethanediyl)

CN .alpha.-(Nonylphenyl)-.omega.-hydroxypolyoxyethylene

CN .omega.-Hydroxy-.alpha.-(nonylphenyl)poly(oxy-1,2-ethanediyl)

CN A 730

CN A 730 (surfactant)

CN Adekatol NP

CN Adekatol NP 1000

CN Adekatol NP 1100

CN Adekatol NP 638

CN Adekatol NP 650

CN Adekatol NP 660

CN Adekatol NP 675

CN Adekatol NP 683

CN Adekatol NP 686

CN Adekatol NP 690

CN Adekatol NP 700

CN Adekatol NP 710

CN Adekatol NP 720

CN Adekatol NP 760

CN Adekatol NP 900

CN Afilan CVH

CN Agral

CN Agral 600

CN Agral 90

CN Agral LN

CN Agral Plus

CN Agral R

CN Akyporox NP 105

CN Akyporox NP 95

CN Alcosist PN

CN Alfenol

CN Alfenol 10

CN Alfenol 18

CN Alfenol 22

CN Alfenol 28

CN Alfenol 710

CN Alfenol 8

CN Alfenol N 8

CN Alkasurf NP

CN Alkasurf NP 11

CN Alkasurf NP 15

CN Alkasurf NP 8

CN Antarox 897

CN Antarox CO

CN Antarox CO 430

CN Antarox CO 530

CN Antarox CO 630

CN Antarox CO 730

CN Antarox CO 850

CN **Nonylphenyl ethoxylate**

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY

DR 12767-68-9, 12789-12-7, 12790-67-9, 9067-50-9, 11098-16-1, 11103-60-9,  
11107-93-0, 172521-16-3, 53529-49-0, 53663-55-1, 53763-35-2, 53763-36-3,  
54174-36-6, 56590-96-6, 57308-02-8, 57571-69-4, 123019-34-1, 123068-21-3,  
124057-60-9, 54985-54-5, 55126-80-2, 55838-69-2, 59330-69-7, 60098-67-1,

60476-27-9, 63798-88-9, 64296-14-6, 64940-97-2, 65035-40-7, 65035-41-8,  
 62229-24-7, 62229-29-2, 63440-03-9, 96957-64-1, 96958-17-7, 96958-28-0,  
 102188-45-4, 99402-83-2, 99531-82-5, 95828-59-4, 96231-61-7, 103939-37-3,  
 105269-88-3, 67053-58-1, 106152-98-1, 114101-89-2, 50855-29-3, 50934-84-4,  
 51609-19-9, 51668-51-0, 51938-59-1, 51938-60-4, 52012-43-8, 61614-07-1,  
 61840-55-9, 62169-44-2, 65777-14-2, 66525-84-6, 37187-23-8, 37210-94-9,  
 37230-99-2, 37280-80-1, 37336-52-0, 111623-62-2, 139281-67-7, 137263-06-0,  
 72847-44-0, 72847-45-1, 74434-41-6, 74656-63-6, 74749-71-6, 76829-05-5,  
 77271-60-4, 142985-89-5, 75882-09-6, 80341-59-9, 143929-07-1, 93095-76-2,  
 83271-48-1, 80966-32-1, 81296-82-4, 30676-83-6, 32196-52-4, 39289-57-1,  
 39316-45-5, 39316-73-9, 39346-85-5, 39373-71-2, 39392-83-1, 39393-36-7,  
 39421-49-3, 39453-05-9, 39454-98-3, 39475-46-2, 42617-03-8, 52038-46-7,  
 52051-49-7, 52434-07-8, 52440-03-6, 52440-78-5, 52440-94-5, 52504-18-4,  
 52504-19-5, 52683-07-5, 53125-17-0, 107231-62-9, 116711-78-5, 188612-23-9,  
 190856-87-2, 205577-03-3, 226225-58-7, 226225-59-8

MF (C2 H4 O)<sub>n</sub> C15 H24 O

CI IDS, PMS, COM


PCT Polyether

LC STN Files: AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,  
 CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB,  
 DETHERM\*, DIOGENES, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA,  
 MSDS-OHS, NIOSHTIC, PDLCOM\*, PIRA, PLASPEC\*, PROMT, RTECS\*, TOXLINE,  
 TOXLIT, ULIDAT, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, TSCA\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)



D1-(CH<sub>2</sub>)<sub>8</sub>-Me

10388 REFERENCES IN FILE CA (1967 TO DATE)

373 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

10396 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L26 ANSWER 1 OF 38 USPATFULL

TI Composition, barrier film, and method for preventing contact dermatitis

PI US 5888520 19990330

SUMM . . . are capable of sensitizing and causing contact dermatitis in many people are antigenic plants of the genus Rhus, such as **poison ivy, poison oak, and poison sumac.**

SUMM Some examples of a derivatized monosaccharide are **ethoxylates** of methyl glucoside, propoxylates of methyl glucoside, propoxylates of methyl glucoside distearate, and methyl glucose dioleate. Preferably, the derivatized monosaccharide is Methyl Gluceth-10 (10 mole **ethoxylate** of methyl glucoside), Methyl Gluceth-20 (20 mole **ethoxylate** of methyl glucoside), PPG-10 Methyl Glucose Ether (10 mole propoxylate of methyl glucoside), PPG-20 Methyl Glucose Ether (20 mole propoxylate. . . .

SUMM Some examples of the derivatized disaccharide and derivatized starch hydrolysate are **ethoxylates** and propoxylates, such as about 10 mole **ethoxylates**, about 20 mole **ethoxylates**, about 10 mole propoxylates, and about 20 mole propoxylates.

SUMM . . . weight, synergistic saccharide is a derivatized monosaccharide;

more preferably, the low molecular weight, synergistic saccharide is Methyl Gluceth-20 (20 mole **ethoxylate** of methyl glucoside).

SUMM . . . gel, or cream. The preferred embodiment may be considered a pre-exposure lotion which protects the skin against allergens such as **poison ivy, oak, sumac, and other irritants.**

DETD Forearms of five human subjects (known to be allergic to **urushiol**, the antigen in Rhus extract) were washed with soap and water and towel-dried. Three test solutions of the above compositions.

DETD . . . method showed that none of the five subjects exhibited an inflammatory response 72 and 120 hours after contact with the **urushiol** antigen. Positive level--2 inflammatory responses were evident at the control sites (no barrier protection) of all five subjects.

CLM What is claimed is:

. . . syrup solids, derivatized monosaccharide, derivatized disaccharide, and derivatized starch hydrolysate, said derivatized monosaccharide is selected from the group consisting of **ethoxylates** of methyl glucoside, propoxylates of methyl glucoside, propoxylates of methyl glucoside distearate, and methyl glucose dioleate, said derivatized disaccharide is selected from the group consisting of about 10 mole **ethoxylates**, about 20 mole **ethoxylates**, about 10 mole propoxylates, about 20 mole propoxylates, said derivatized starch hydrolysate is selected from the group consisting of about 10 mole **ethoxylates**, about 20 mole **ethoxylates**, about 10 mole propoxylates, and about 20 mole propoxylates; (3) a solvent; and (4) an additive agent; said additive agent. . . .  
4. The composition of claim 1, wherein derivatized monosaccharide is about 20 mole **ethoxylate** of methyl glucoside.

. . . syrup solids, derivatized monosaccharide, derivatized disaccharide, and derivatized starch hydrolysate, said derivatized monosaccharide is selected from the group consisting of **ethoxylates** of methyl glucoside, propoxylates of methyl glucoside, propoxylates of methyl glucoside distearate, and methyl glucose dioleate, said derivatized disaccharide is selected from the group consisting of about 10 mole

**ethoxylates**, about 20 mole **ethoxylates**, about 10 mole  
propoxylates, about 20 mole propoxylates, said derivatized starch  
hydrolysate is selected from the group consisting of about 10 mole  
**ethoxylates**, about 20 mole **ethoxylates**, about 10 mole  
propoxylates, and about 20 mole propoxylates; (3) a solvent; and (4) an  
additive agent, said additive agent. . . .  
11. The method of claim 8, wherein derivatized monosaccharide is about  
20 mole **ethoxylate** of methyl glucoside.

L26 ANSWER 15 OF 38 USPATFULL

TI Kappa agonist compounds and pharmaceutical formulations thereof

PI US 5646151 19970708

SUMM . . . such as abrasions, burns, sunburn, superficial cuts, surgical incisions, toothaches, contusions, irritations, inflammatory skin conditions, including but not limited to **poison ivy**, and allergic rashes and dermatitis and any condition that yields a hyperalgesic pain state and other such conditions.

SUMM (e) **Ethoxylated** glycerides, such as **ethoxylated** glyceryl monostearate.

SUMM (j) Fatty alcohol ethers, including, but not limited to, **ethoxylated** fatty alcohols of 10 to 20 carbon atoms, such as, but are not limited to, the lauryl cetyl, stearyl, isostearyl, . . .

SUMM (k) Ether-esters, such as fatty acid esters of **ethoxylated** fatty alcohols.

SUMM . . . Lanolin and derivatives, including but not limited to, lanolin,

lanolin oil, lanolin wax, lanolin alcohols, lanolin fatty acids, isopropyl lanolate, **ethoxylated** lanolin, **ethoxylated** lanolin alcohols, **ethoxylated** cholesterol, propoxylated lanolin alcohols, acetylated lanolin, acetylated lanolin alcohols, lanolin alcohols linoleate, lanolin alcohols ricinoleate, acetate of lanolin alcohols ricinoleate, acetate of **ethoxylated** alcohols-esters, hydrogenolysis of lanolin, **ethoxylated** hydrogenated lanolin, **ethoxylated** sorbitol lanolin, and liquid and semisolid lanolin absorption bases.

SUMM . . . including, but not limited to, propylene glycol, dipropylene glycol, polypropylene glycol [M.W. 2000-4000], polyoxyethylene polyoxypropylene glycols, polyoxypropylene polyoxyethylene glycols, glycerol, **ethoxylated** glycerol, propoxylated glycerol, sorbitol, **ethoxylated** sorbitol, hydroxypropyl sorbitol, polyethylene glycol [M.W. 200-6000], methoxy polyethylene glycols 350, 550, 750, 2000, 5000, poly(ethylene oxide) homopolymers [M.W. 100,000-5,000,000], . . .

SUMM . . . 200-6000], mono- and di-fatty esters, propylene glycol mono- and di-fatty acid esters, polypropylene glycol 2000 monooleate, polypropylene glycol 2000 monostearate, **ethoxylated** propylene glycol monostearate, glyceryl mono- and di-fatty acid esters, polyglycerol poly-fatty acid esters, **ethoxylated** glyceryl monostearate, 1,3-butylene glycol monostearate, 1,3-butylene glycol distearate, polyoxyethylene polyol fatty acid ester, sorbitan fatty

acid esters, and polyoxyethylene sorbitan. . .

SUMM . . . stearyl stearate and beeswax derivatives, including, but not limited to, polyoxyethylene sorbitol beeswax, which are reaction products of beeswax with **ethoxylated** sorbitol of varying ethylene oxide content that form a mixture of ether-esters.

SUMM (s) Amides, such as fatty acid amides, **ethoxylated** fatty acid amides, and solid fatty acid alkanolamides.

L26 ANSWER 8 OF 38 USPATFULL

TI Treatment of pruritus with vitamin D and analogs thereof

PI US 5789399 19980804

DRWD . . . FIGURE illustrates the concentration-response relationship of the antipruritic effect of vitamin D.sub.3 (0.25-5.0 .mu.g/ml) in alleviating the itching produced by **poison ivy**.

DETD . . . salts, acyl lactylates, alkyl ether carboxylates, N-Acyl Sarcosinates, N-Acyl Glutamates, fatty acid-polypeptide condensates, sulfuric acid esters including alkyl sulfates and **ethoxylated** alkyl sulfates, ester-linked sulfonates, alpha olefin sulfonates, phosphated **ethoxylated** alcohols; (2) cationic surfactants such as monoalkyl quaternary ammonium salts, dialkyl quaternary ammonium compounds, amidoamines and aminimides; (3) amphoteric surfactants. .

as N-substituted alkyl amides, N-alkyl betaines, sulfobetaines, and N-alkyl beta-aminopropionates; and (4) nonionic surfactants such as (a) polyoxyethylene compounds including **ethoxylated** alcohols, **ethoxylated** esters and **ethoxylated** amines; (b) polyoxypropylene compounds such as propoxylated alcohols, **ethoxylated**/propoxylated block polymers and propoxylated esters; (c) alkanolamines; (d) amine oxides; and (e) fatty acid esters of polyhydric alcohols such as. . .

DETD . . . are intended for treatment by the present invention include but

are not limited to chickenpox, shingles, plant toxins such as **poison ivy**, insect bites, chronic kidney failure, liver diseases such as primary biliary cirrhosis and alcoholic cirrhosis, malabsorption syndromes such as steatorrhea, . . .

DETD This example illustrates the antipruritic effect of vitamin D.sub.3 formulated in water-based emulsions in alleviating the pruritus caused by **poison ivy**.

DETD Subject MS contracted **poison ivy** rash and tested the various preparations above. Preparations were evaluated by the subject after application to an area of rash. . . .

DETD This example illustrates the antipruritic effect of vitamin D.sub.3 formulated in oil-based preparations in alleviating the pruritus caused by **poison ivy**.

DETD This example illustrates the antipruritic effect of vitamin D.sub.3 formulated in a water-based suspension in alleviating the pruritus caused by **poison ivy**.

DETD . . . new treatment. It will be explained that this is a trial of a cream that relieves itchiness in chickenpox and **poison ivy** and that it may or may not help them.

L26 ANSWER 7 OF 38 USPATFULL

TI Composition, barrier film, and method for preventing contact dermatitis  
PI US 5837266 19981117

DETD . . . are capable of sensitizing and causing contact dermatitis in many people are antigenic plants of the genus Rhus, such as **poison ivy, poison oak, and poison sumac.**

DETD Some examples of a derivatized monosaccharide are **ethoxylates** of methyl glucoside, propoxylates of methyl glucoside, propoxylates of methyl glucoside distearate, and methyl glucose dioleate. Preferably, the derivatized monosaccharide is Methyl Gluceth-10 (10 mole **ethoxylate** of methyl glucoside), Methyl Gluceth-20 (20 mole **ethoxylate** of methyl glucoside), PPG-10 Methyl Glucose Ether (10 mole propoxylate of methyl glucoside), PPG-20 Methyl Glucose Ether (20 mole propoxylate. . . .

DETD Some examples of the derivatized disaccharide and derivatized starch hydrolysate are **ethoxylates** and propoxylates, such as about 10 mole **ethoxylates**, about 20 mole **ethoxylates**, about 10 mole propoxylates, and about 20 mole propoxylates.

DETD . . . weight, synergistic saccharide is a derivatized monosaccharide;

more preferably, the low molecular weight, synergistic saccharide is Methyl Gluceth-20 (20 mole **ethoxylate** of methyl glucoside).

DETD . . . gel, or cream. The preferred embodiment may be considered a pre-exposure lotion which protects the skin against allergens such as **poison ivy, oak, sumac, and other irritants.**

DETD Forearms of five human subjects (known to be allergic to **urushiol**, the antigen in Rhus extract) were washed with soap and water and towel-dried. Three test solutions of the above compositions.

DETD . . . method showed that none of the five subjects exhibited an inflammatory response 72 and 120 hours after contact with the **urushiol** antigen. Positive level-2 inflammatory responses were evident at the control sites (no barrier protection) of all five subjects.

CLM What is claimed is:

. . . syrup solids, derivatized monosaccharide, derivatized disaccharide, and derivatized starch hydrolysate, said derivatized monosaccharide is selected from the group consisting of **ethoxylates** of methyl glucoside, propoxylates of methyl glucoside, propoxylates of methyl glucoside distearate, and methyl glucose dioleate, said derivatized disaccharide is selected from the group consisting of about 10 mole **ethoxylates**, about 20 mole **ethoxylates**, about 10 mole propoxylates, about 20 mole propoxylates, said derivatized starch hydrolysate is selected from the group consisting of about 10 mole **ethoxylates**, about 20 mole **ethoxylates**, about 10 mole propoxylates, and about 20 mole propoxylates; (3) a solvent; and (4) optionally one or more additives.

3. The composition of claim 1, wherein derivatized monosaccharide is about 20 mole **ethoxylate** of methyl glucoside.

. . . syrup solids, derivatized monosaccharide, derivatized disaccharide, and derivatized starch hydrolysate, said derivatized monosaccharide is selected from the group consisting of **ethoxylates** of methyl glucoside, propoxylates of methyl glucoside, propoxylates of methyl glucoside distearate, and methyl glucose dioleate, said derivatized disaccharide is selected from the group consisting of about 10 mole

**ethoxylates**, about 20 mole **ethoxylates**, about 10 mole  
propoxylates, about 20 mole propoxylates, said derivatized starch  
hydrolysate is selected from the group consisting of about 10 mole  
**ethoxylates**, about 20 mole **ethoxylates**, about 10 mole  
propoxylates, and about 20 mole propoxylates; (3) a solvent; and (4)  
optionally one or more additives.

20 9. The method of claim 7, wherein derivatized monosaccharide is about  
mole **ethoxylate** of methyl glucoside.



L92 ANSWER 2 OF 15 CAPLUS COPYRIGHT 1999 ACS

AB The title compns. comprise hardened castor oil **ethoxylate**, N-acylamino acid salts, N-methyltaurine salts or anionic surfactants, and amphoteric surfactants at the N-acylamino acid salts/N-methyltaurine salt ratio 0.1-1.0 and the castor oil **ethoxylate**/(anionic + amphoteric surfactant) ratio 0.1-10.0. A compn. comprised hardened castor

oil **ethoxylate** 8.0, Na N-myristoyl-L-glutamate 2.5, Na lauryl-N-methyltaurinate 2.5, 2-lauryl-N-carboxymethyl-N-hydroxyethylimidazolium betaine 3.0, and water to 100%.

ST detergent compn castor oil **ethoxylate**; amino acid detergent shampoo

IT 107-35-7D, Taurine, cocoyl, salts **137-16-6**, Sodium N-lauroylsarcosinate 683-10-3 21539-58-2 25322-68-3D, Polyethylene glycol, hardened castor oil derivs. 26038-93-7 38079-62-8, Sodium N-stearoyl-L-glutamate 38517-37-2 66451-67-0 70411-33-5

RL: TEM (Technical or engineered material use); USES (Uses)  
(mild detergent compns. with good foaming giving clean feel after use for body and hair shampoos)

L92 ANSWER 3 OF 15 CAPLUS COPYRIGHT 1999 ACS

ST amine oxide surfactant mixt foaming; betaine surfactant mixt foaming; alkanolamide surfactant mixt foaming; amide alkanol surfactant mixt foaming; **ethoxylate** surfactant mixt foaming; sulfate surfactant mixt foaming; polyethylene glycol surfactant mixt foaming; alkylbenzenesulfonate surfactant mixt foaming; sarcosinate alkyl surfactant mixt. . .

IT 111-42-2D, Diethanolamine, amides with coco fatty acids 151-21-3, Sodium

lauryl sulfate, uses 1643-20-5, Dodecyldimethylamine oxide 2571-88-2, Dimethyloctadecylamine oxide 2601-33-4 2605-78-9, Dimethyloctylamine oxide 2605-79-0, Decyldimethylamine oxide 3332-27-2, Dimethyltetradecylamine oxide 7128-91-8, Hexadecyldimethylamine oxide **7631-98-3**, Sodium lauryl sarcosinate 9004-82-4, Sodium lauryl ether sulfate 9016-45-9, Polyethylene glycol mono(nonylphenyl) ether 25155-30-0, Sodium dodecylbenzenesulfonate 25322-68-3, Polyethylene glycol 25322-68-3D, Polyethylene glycol, monoalkyl ethers 25322-69-4, Polypropylene glycol 36574-66-0D, amides with coco fatty acids 100545-50-4, Didecylmethylamine oxide 153766-17-7

RL: USES (Uses)  
(surfactant mixts. contg., foaming)

L92 ANSWER 5 OF 15 CAPLUS COPYRIGHT 1999 ACS

ST hypochlorite thickener cleaner stability; amine oxide hypochlorite cleaner; sulfate **ethoxylate** hypochlorite

IT 5136-55-0 **7631-98-3** 9004-82-4 30364-51-3

RL: USES (Uses)  
(cleaning compns. contg. hypochlorite and, liq., thickened, stable)

L92 ANSWER 6 OF 15 CAPLUS COPYRIGHT 1999 ACS

AB . . . water 50-80%, having a neat viscosity 2000-12,000 cP and a dil. viscosity (50%) of 15-95 cP. Thus 28.5% sodium lauryl **ethoxylate** sulfate 39.3, 28.5% Na lauryl sulfate 32.2, coconut monoethanolamide 4.0, perfume 3, ethylene glycol distearate, EDTA 0.1, preservatives 0.25, color. . .

IT 57-55-6, uses and miscellaneous 107-21-1, uses and miscellaneous  
**137-16-6** 151-21-3, uses and miscellaneous 627-83-8 9004-32-4  
9004-62-0 9004-64-2 9041-56-9 14807-96-6, uses and miscellaneous  
15826-16-1 25322-68-3 25322-69-4 37353-59-6

RL: USES (Uses)

(liq. cleaning compns. contg., with low electrolyte level)

L92 ANSWER 7 OF 15 CAPLUS COPYRIGHT 1999 ACS

AB . . . (23.65%). A mouthwash for use with the toothpaste contained chlorhexidine digluconate (II) [18472-51-0] (1.80), saccharin (0.05), 1,2-propanediol (3.50), fatty alc. **ethoxylate** (1.20), 95% EtOH (8.00), fragrance (0.80), and water (84.65%).

IT 56-95-1 **137-16-6** 151-21-3, biological studies 1847-58-1  
3697-42-5 18472-51-0 38901-23-4 51903-49-2

RL: BIOL (Biological study)

L26 ANSWER 1 OF 38 USPATFULL  
PI US 5888520 19990330  
TI Composition, barrier film, and method for preventing contact dermatitis

L26 ANSWER 2 OF 38 USPATFULL  
PI US 5869521 19990209  
TI Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith

L26 ANSWER 3 OF 38 EUROPATFULL COPYRIGHT 1999 WILA  
PI EP 632717 B1 19980708  
TIEN AGENT FOR USE AS AN ANTI-IRRITANT.

L26 ANSWER 4 OF 38 USPATFULL  
PI US 5851540 19981222  
TI Composition, barrier film, and method for preventing contact dermatitis

L26 ANSWER 5 OF 38 USPATFULL  
PI US 5849762 19981215  
TI Peripherally acting anti-pruritic opiates

L26 ANSWER 6 OF 38 USPATFULL  
PI US 5849761 19981215  
TI Peripherally active anti-hyperalgesic opiates

L26 ANSWER 7 OF 38 USPATFULL  
PI US 5837266 19981117  
TI Composition, barrier film, and method for preventing contact dermatitis

L26 ANSWER 8 OF 38 USPATFULL  
PI US 5789399 19980804  
TI Treatment of pruritus with vitamin D and analogs thereof

L26 ANSWER 9 OF 38 USPATFULL  
PI US 5763445 19980609  
TI Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith

L26 ANSWER 10 OF 38 USPATFULL  
PI US 5760023 19980602  
TI Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith

L26 ANSWER 11 OF 38 USPATFULL  
PI US 5744458 19980428  
TI Kappa agonist compounds and pharmaceutical formulations thereof

L26 ANSWER 12 OF 38 CAPLUS COPYRIGHT 1999 ACS  
PATENT NO. KIND DATE APPLICATION NO. DATE  
-----  
PI WO 9740813 A1 19971106 WO 1997-US7748 19970428

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,  
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,  
GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,

L92	ANSWER 2 OF 15 CAPLUS COPYRIGHT 1999 ACS				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 07062389	A2	19950307	JP 1993-291193	19931027
TI	Mild detergent compositions with good foaming giving clean feel after use for body and hair shampoos				
L92	ANSWER 3 OF 15 CAPLUS COPYRIGHT 1999 ACS				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	ZA 9203280	A	19930428	ZA 1992-3280	19920506
TI	Surfactant mixtures having an amine oxide, betaine, or alkanolamide component				
L92	ANSWER 5 OF 15 CAPLUS COPYRIGHT 1999 ACS				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 8601823	A1	19860327	WO 1985-FR257	19850920
	W: DK, FI, KR, NO, SE				
	FR 2570713	A1	19860328	FR 1984-14508	19840921
	BE 903274	A1	19860320	BE 1985-215608	19850920
	FI 8602045	A	19860515	FI 1986-2045	19860515
	FI 84915	B	19911031		
	FI 84915	C	19920210		
	NO 8601930	A	19860515	NO 1986-1930	19860515
	NO 166192	B	19910304		
	NO 166192	C	19910612		
	SE 8602275	A	19860520	SE 1986-2275	19860520
	SE 463565	B	19901210		
	SE 463565	C	19910411		
	DK 8602378	A	19860521	DK 1986-2378	19860521
	DK 164117	B	19920511		
	DK 164117	C	19921005		
TI	Aqueous thickened cleaning compositions				
L92	ANSWER 6 OF 15 CAPLUS COPYRIGHT 1999 ACS				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 166608	A2	19860102	EP 1985-304540	19850626
	EP 166608	A3	19890705		
	R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
	GB 2160888	A1	19860102	GB 1985-16174	19850626
	GB 2160888	B2	19871223		
	AU 8544237	A1	19860102	AU 1985-44237	19850627
	AU 583830	B2	19890511		
	CA 1242950	A1	19881011	CA 1985-485463	19850627
	JP 61081496	A2	19860425	JP 1985-142403	19850628
	US 4917823	A	19900417	US 1988-277463	19881123
TI	Liquid cleansing compositions				
L92	ANSWER 7 OF 15 CAPLUS COPYRIGHT 1999 ACS				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 2430280	A1	19760108	DE 1974-2430280	19740624
TI	Composition and system for cleaning and care of human teeth				

L26 ANSWER 16 OF 38 USPATFULL  
TI Cleansing and disinfecting method  
PI US 5620527 19970415

L26 ANSWER 17 OF 38 USPATFULL  
TI Agent for use as an anti-irritant  
PI US 5476853 19951219  
WO 9318744 19930930

L26 ANSWER 18 OF 38 USPATFULL  
TI Therapeutic compositions containing benzoyl peroxide  
PI US 5086075 19920204

L26 ANSWER 19 OF 38 USPATFULL  
TI Cosmetic compositions  
PI US 4963591 19901016

L26 ANSWER 20 OF 38 USPATFULL  
TI Oxazolidinone penetration enhancing compounds  
PI US 4960771 19901002

L26 ANSWER 21 OF 38 USPATFULL  
TI Cleansing and disinfecting compositions  
PI US 4941989 19900717

L26 ANSWER 22 OF 38 USPATFULL  
TI Therapeutic compositions containing benzoyl peroxide  
PI US 4923900 19900508

L26 ANSWER 23 OF 38 USPATFULL  
TI Cleansing and disinfecting compositions, including bleaching agents,  
and sponges and other applicators incorporating the same  
PI US 4847089 19890711

L26 ANSWER 24 OF 38 USPATFULL  
TI Cooling anti-itch skin preparations  
PI US 4797402 19890110

L26 ANSWER 25 OF 38 CAPLUS COPYRIGHT 1999 ACS  
TI Control of selected perennial weeds with glyphosate

L26 ANSWER 26 OF 38 USPATFULL  
TI Method of relieving pain and inflammatory conditions employing  
substituted salicylamides  
PI US 4742083 19880503

L26 ANSWER 27 OF 38 USPATFULL  
TI Method of relieving pain and inflammatory conditions employing  
substituted salicylamides  
PI US 4725590 19880216

L26 ANSWER 28 OF 38 USPATFULL  
TI Method of relieving pain and inflammatory conditions employing  
substituted salicylamides  
PI US 4560549 19851224

L26 ANSWER 29 OF 38 USPATFULL  
TI Urea derivatives

PI US 4460602 19840717

L26 ANSWER 30 OF 38 USPATFULL

TI Carbamate derivatives

PI US 4443473 19840417

L26 ANSWER 31 OF 38 USPATFULL

TI Hydroxyphenylacetamides having analgesic and anti-irritant activity

PI US 4424205 19840103

L26 ANSWER 32 OF 38 USPATFULL

TI Novel sulfonamide derivatives

PI US 4401663 19830830

L26 ANSWER 33 OF 38 USPATFULL

TI Anesthetic compositions containing benzocaine

PI US 4344965 19820817

L26 ANSWER 34 OF 38 USPATFULL

TI Topical acylaminophenols

PI US 4329366 19820511

L26 ANSWER 35 OF 38 USPATFULL

TI Method of treating dermatitis venenata

PI US 4199575 19800422

L26 ANSWER 36 OF 38 USPATFULL

TI Injectable solutions and processes of using such

PI US 4196218 19800401

L26 ANSWER 37 OF 38 USPATFULL

TI Injectable solutions and processes of using such

PI US 3982017 19760921

L26 ANSWER 38 OF 38 USPATFULL

TI FIRE FIGHTING METHOD EMPLOYING SOLUTIONS OF PVA AND ALKALI METAL BORATE

PI US 3719515 19730306

CN Soypon SLP  
DR 75195-12-9  
MF C15 H29 N O3 . Na  
CI COM  
LC STN Files: AGRICOLA, BEILSTEIN\*, BIOBUSINESS, BIOSIS, CA, CAOLD,  
CAPLUS,  
CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, EMBASE, HODOC\*, IFICDB,  
IFIPAT, IFIUDB, IPA, MRCK\*, MSDS-OHS, PIRA, PROMT, TOXLINE, TOXLIT,  
USPATFULL  
(\*File contains numerically searchable property data)  
Oth

L78 ANSWER 1 OF 2 REGISTRY COPYRIGHT 1999 ACS  
RN 7631-98-3 REGISTRY  
CN Glycine, N-dodecyl-N-methyl-, sodium salt (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Sarcosine, N-dodecyl-, sodium salt (7CI, 8CI)  
OTHER NAMES:  
CN Crodasinic LS 30  
CN Laurylsarcosine sodium salt  
CN Sodium laurylsarcosinate  
CN Sodium laurylsarcosine  
CN Sodium N-dodecylsarcosinate  
CN Sodium N-laurylsarcosinate  
CN Triton WR 1340  
MF C15 H31 N O2 . Na  
LC STN Files: BEILSTEIN\*, BIOSIS, CA, CAOLD, CAPLUS, CHEMCATS, CHEMLIST,  
CSCHEM, EMBASE, IFICDB, IFIPAT, IFIUDB, RTECS\*, TOXLINE, TOXLIT,  
USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)  
CRN (15930-65-1)



ML, MR, NE, SN, TD, TG  
US 5837266 A 19981117  
US 5851540 A 19981222  
AU 9728314 A1 19971119  
EP 896521 A1 19990217

US 1996-642227 19960430  
US 1997-824282 19970326  
AU 1997-28314 19970428  
EP 1997-922717 19970428

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

TI Composition, barrier film, and method for preventing contact dermatitis

L26 ANSWER 13 OF 38 USPATFULL

PI US 5688955 19971118

TI Kappa agonist compounds and pharmaceutical formulations thereof

L26 ANSWER 14 OF 38 USPATFULL

PI US 5650157 19970722

TI Pharmaceutical compositions and methods

L26 ANSWER 15 OF 38 USPATFULL

PI US 5646151 19970708

TI Kappa agonist compounds and pharmaceutical formulations thereof